| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | 55% total growth, 17% organic base business growth. |
|---|---|
| Margins | EBITDA margins expanded to 33.8% due to merger cost synergies. |
| Demand visibility | Strong chronic demand in India; base business outperforming IPM growth. |
| Management confidence | Balanced; optimistic on synergies but admits Brazil Semaglutide delay miss. |
Growth
Revenue grew 55%, with JB merger contributing significantly. Organic growth led by Brazil (27%) and India (19%).
Outlook
Guided double-digit growth for JB India RX business; net debt/EBITDA stands at 2.07x.
Risks
Semaglutide supply setback in India and loss of first-mover advantage for Semaglutide in Brazil.
Earnings Call Transcript filed with NSE, NSE: TORNTPHARM. Summary written with AI assistance from the document.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,988.50
- Market cap
- ₹1,89,747 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 87.0×Sector 50.4×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.97%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Annual General Meeting
Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.
Torrent Pharmaceuticals Q1 FY27 Results: Net Profit ₹566 Cr, Up 3.3% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,921 Cr (+54.8% YoY) and net profit of ₹566 Cr (+3.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹566 Cr · +3.3% YoY
Torrent Pharmaceuticals Earnings Call: Key Takeaways
Torrent Pharma Q4 FY26 revenue rose 42% to ₹4,197cr, driven by JB Pharma consolidation. Combined EBITDA margin stood at 32.3%, with focus on Semaglutide ramp-up in India and synergy execution.
Torrent Pharmaceuticals Earnings Call: Key Takeaways
Torrent Pharma delivered strong Q4 growth led by India and Brazil, while successfully integrating Curatio and JB Pharma assets.
Torrent Pharmaceuticals Q4 FY26 Results: Net Profit ₹364 Cr, Down 26.9% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,197 Cr (+41.8% YoY) and net profit of ₹364 Cr (-26.9% YoY) for Q4 FY26.
- Key figure
- Net profit ₹364 Cr · -26.9% YoY